Skip to content
The Policy VaultThe Policy Vault

Jakafi (ruxolitinib) — Medica

Accelerated or Blast Phase Myeloproliferative Neoplasm

Initial criteria

  • age ≥ 18 years
  • patient has at least one disease-related symptom

Approval duration

1 year